Aurinia Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Arthur He assumed coverage of Aurinia Pharmaceuticals (AUPH) with a Buy rating and $17 price target Aurinia is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, the analyst tells investors in a research note. The firm believes has a “solid and sustainable” foundation with its lupus nephritis franchise.